Eli Lilly plans to build a new US$2.5 billion cutting-edge manufacturing site in Alzey, Germany.
This state-of-the-art facility equipped with cutting-edge technology will empower to consistently provide medicines prioritising safety above all and ensuring top-notch quality worldwide.
The new facility will expand the manufacturing network for injectable products demonstrates a commitment to meeting the growing demand for medications, particularly those related to diabetes and obesity.
The facility plans to hire around 1,000 proficient individuals encompassing engineers, operators, and scientists. The integration of automation and cutting-edge technology not only enhances efficiency but also ensures precision and quality in the manufacturing process to create transformative pharmaceuticals.
In addition, an approximate 1,900 positions are expected to emerge during the construction phase, set to commence in 2024.
Starting in 2027, the new site will serve as a crucial factor in enhancing production of incretin, strengthening its supply chain significantly.
Name Eli Lilly
Type New Construction
Budget US$2.5 billion